{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-23-013555","form_type":"8-K","ticker":"CVM","cik":"0000725363","company_name":"CEL SCI CORP","filed_at":"2023-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.832307+00:00","generated_at":"2026-06-09T06:19:18.304998+00:00","sec_items":["1.01","5.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"CEL-SCI reports Multikine cuts death risk by half in target head & neck cancer patients; seeks accelerated approval","bullets":["CEO Geert Kersten's employment extended to August 31, 2027.","Multikine shows 28.6% absolute 5-year overall survival benefit vs control (p=0.0015) in target population.","Hazard ratio 0.349; risk of death cut in half at 5 years in target patients.",">35% pre-surgery tumor reductions/downstages (p<0.01) with low PD-L1 expression.","Company plans conditional/accelerated approval worldwide without waiting for new trial."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-23-013555","json":"https://secwatch.observer/filing/0001654954-23-013555.json","markdown":"https://secwatch.observer/filing/0001654954-23-013555.md","text":"https://secwatch.observer/filing/0001654954-23-013555.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/725363/000165495423013555/0001654954-23-013555-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/725363/000165495423013555/cvm_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T06:19:18.304998+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}